tiprankstipranks

Adverum Biotechnologies reports Q1 EPS ($2.25), consensus ($1.97)

Cash, cash equivalents and short-term investmentswere $83.1M as of March 31, compared to $125.7M as of December 31, 2024. Adverum expects its cash, cash equivalents and short-term investments to fund operations into the second half of 2025.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1